Welcome to our dedicated page for Exponent news (Ticker: EXPO), a resource for investors and traders seeking the latest updates and insights on Exponent stock.
Exponent Inc (EXPO) is a global leader in multidisciplinary engineering and scientific consulting, addressing complex challenges across industries from transportation to healthcare. This page serves as the definitive source for all company announcements, financial updates, and strategic developments.
Investors and industry stakeholders will find curated EXPO news including earnings reports, partnership announcements, and operational updates. Key updates cover engineering consulting innovations, safety analysis advancements, and regulatory compliance insights that demonstrate the company's technical leadership.
Bookmark this page to track EXPO's progress in solving high-stakes technical challenges through press releases detailing new service offerings, expert commentary on industry trends, and corporate milestones. All content is verified for accuracy and updated systematically to support informed decision-making.
Exponent Inc. (Nasdaq: EXPO) has declared a quarterly cash dividend of $0.20 per share, payable on September 24, 2021, to stockholders of record as of September 10, 2021. This decision reflects the company’s strong balance sheet and business resilience. Exponent aims to continue its quarterly dividend payouts in March, June, September, and December. CEO Dr. Catherine Corrigan highlighted the firm’s commitment to delivering valuable solutions to complex challenges, ensuring long-term shareholder value.
Exponent, Inc. (Nasdaq: EXPO) reported strong Q2 2021 results, with net revenue up 30% to $119.9 million, driven by robust demand post-pandemic. EBITDA margin expanded 630 basis points year-over-year, reaching 32.3% of net revenues. Net income increased to $25.4 million, or $0.48 per diluted share, compared to $16.3 million in Q2 2020. The company maintains a positive outlook for the remainder of the year, expecting low-double digit revenue growth and increased EBITDA margins. Exponent reported $240 million in cash and repurchased $7 million of stock.
Exponent, Inc. (EXPO) will report its Q2 fiscal year 2021 financial results on July 29, 2021, after market close. Dr. Catherine Corrigan, CEO, and Richard Schlenker, CFO, will host a conference call at 4:30 p.m. ET to discuss the results. The call will be accessible via a live and archived webcast on the company's Investor Relations website. A telephonic replay will be available until August 5, 2021. Exponent specializes in engineering and scientific consulting, leveraging over 50 years of experience in solving complex problems across various technical disciplines.
Exponent, Inc. (NASDAQ: EXPO) announced the appointment of John Doyle, Dr.P.H., as Group Vice President, Health Sciences on May 17, 2021. Dr. Doyle will lead the company's Health Sciences team, addressing environmental, occupational, medical, and public health challenges. CEO Dr. Catherine Corrigan highlighted Dr. Doyle's experience in healthcare research and the pharmaceutical sector, aiming to drive growth in life sciences. Dr. Doyle has authored over 200 research articles, primarily in oncology, and holds advanced degrees in Epidemiology from Columbia University.
Exponent, Inc. (Nasdaq:EXPO) announced that CEO Dr. Catherine Corrigan and CFO Richard Schlenker will present at the Berenberg Conference USA 2021 on May 18, 2021, at 11:00 AM PT. Investors can access a live webcast of this presentation on Exponent's investor relations website, with an archived replay available afterward. Exponent is known for its engineering and scientific consulting, leveraging over 50 years of experience to tackle complex challenges across various sectors.
Exponent, Inc. (Nasdaq:EXPO) declared a quarterly cash dividend of $0.20 per share, to be paid on June 25, 2021, to stockholders of record as of June 11, 2021. The company has consistently increased dividends, marking the eighth consecutive year of growth, reflecting its strong balance sheet and commitment to long-term shareholder value. Exponent plans to continue quarterly dividends in March, June, September, and December, contingent upon Board approval.
Exponent, Inc. (Nasdaq:EXPO) reported a 10% increase in net revenues for Q1 FY2021, totaling $116.5 million. EBITDA rose to $31.8 million, reflecting a margin improvement of 400 basis points year-over-year. Net income grew to $30.8 million or $0.58 per diluted share. The engineering segment contributed 81% of revenues with an 11% growth, while the environmental segment saw a 7% increase. Exponent anticipates continued growth with Q2 revenue growth projected in the low twenties and full-year guidance in the high-single to low-double digits.
Exponent, Inc. (Nasdaq: EXPO) announced it will report its first quarter fiscal year 2021 financial results on April 29, 2021, after market close. The conference call hosted by CEO Dr. Catherine Corrigan and CFO Richard Schlenker will begin at 4:30 p.m. ET. Shareholders can access the call live or via archived webcast on the company's Investor Relations page. A telephonic replay will also be available until May 6, 2021.
Exponent, Inc. (Nasdaq:EXPO) announced that CEO Dr. Catherine Corrigan and CFO Richard Schlenker will present at the Truist Securities Technology, Internet & Services Summit on March 9, 2021, from 8:20am to 9:00am PT. A webcast of the event will be available on the investor relations section of Exponent's website, where an archived replay will also be provided afterward. Exponent specializes in engineering and scientific consulting, aiding clients in complex challenges through over 50 years of experience.
Dr. Catherine Ford Corrigan was elected to the National Academy of Engineering on February 9, 2021, a significant honor in the field of engineering. She is recognized for her impactful research in injury mechanics and her leadership roles in biomechanical engineering and scientific consulting at Exponent. Over 25 years, Dr. Corrigan has cultivated talent among engineers, scientists, and regulatory experts, thus enhancing the firm's reputation. Paul R. Johnston, Chairman of Exponent, praised her leadership in maintaining scientific excellence.